These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 22053974)

  • 1. CCL5: a double-edged sword in host defense against the hepatitis C virus.
    Katsounas A; Schlaak JF; Lempicki RA
    Int Rev Immunol; 2011; 30(5-6):366-78. PubMed ID: 22053974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CCL5 mRNA is a marker for early fibrosis in chronic hepatitis C and is regulated by interferon-α therapy and toll-like receptor 3 signalling.
    Katsounas A; Trippler M; Wang B; Polis M; Lempicki RA; Kottilil S; Gerken G; Schlaak JF
    J Viral Hepat; 2012 Feb; 19(2):128-37. PubMed ID: 22239502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Liver-derived hepatitis C virus (HCV)-specific CD4(+) T cells recognize multiple HCV epitopes and produce interferon gamma.
    Schirren CA; Jung MC; Gerlach JT; Worzfeld T; Baretton G; Mamin M; Hubert Gruener N; Houghton M; Pape GR
    Hepatology; 2000 Sep; 32(3):597-603. PubMed ID: 10960455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of chemokines as inflammatory mediators in chronic hepatitis C virus infection.
    Zeremski M; Petrovic LM; Talal AH
    J Viral Hepat; 2007 Oct; 14(10):675-87. PubMed ID: 17875002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathophysiology of hepatitis C virus infection and related liver disease.
    Pawlotsky JM
    Trends Microbiol; 2004 Feb; 12(2):96-102. PubMed ID: 15036326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis C virus (HCV): a review of immunological aspects.
    Irshad M; Khushboo I; Singh S; Singh S
    Int Rev Immunol; 2008; 27(6):497-517. PubMed ID: 19065353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathological Roles of Interleukin-22 in the Development of Recurrent Hepatitis C after Liver Transplantation.
    Gao Y; Ren H; Meng F; Li J; Cheung E; Li H; Zhao J; Liu H; Liu Z; Zhang M
    PLoS One; 2016; 11(4):e0154419. PubMed ID: 27123854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatitis C virus E2 and CD81 interaction may be associated with altered trafficking of dendritic cells in chronic hepatitis C.
    Nattermann J; Zimmermann H; Iwan A; von Lilienfeld-Toal M; Leifeld L; Nischalke HD; Langhans B; Sauerbruch T; Spengler U
    Hepatology; 2006 Oct; 44(4):945-54. PubMed ID: 17006905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C.
    Promrat K; McDermott DH; Gonzalez CM; Kleiner DE; Koziol DE; Lessie M; Merrell M; Soza A; Heller T; Ghany M; Park Y; Alter HJ; Hoofnagle JH; Murphy PM; Liang TJ
    Gastroenterology; 2003 Feb; 124(2):352-60. PubMed ID: 12557141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adaptive immune responses in acute and chronic hepatitis C virus infection.
    Bowen DG; Walker CM
    Nature; 2005 Aug; 436(7053):946-52. PubMed ID: 16107834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunopathogenesis in hepatitis C virus cirrhosis.
    Spengler U; Nattermann J
    Clin Sci (Lond); 2007 Feb; 112(3):141-55. PubMed ID: 17199558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Role of the Regulatory T lymphocytes in hepatitis C fibrosis progression].
    Delhem N; Cottrez F; Carpentier A; Miroux C; Moralès O; François V; Groux H; Auriault C; Pancré V
    Bull Cancer; 2008 Nov; 95(11):1029-38. PubMed ID: 19036674
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphocyte subset characterization associated with persistent hepatitis C virus infection and subsequent progression of liver fibrosis.
    Yoshida K; Ohishi W; Nakashima E; Fujiwara S; Akahoshi M; Kasagi F; Chayama K; Hakoda M; Kyoizumi S; Nakachi K; Hayashi T; Kusunoki Y
    Hum Immunol; 2011 Oct; 72(10):821-6. PubMed ID: 21712057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Innate immunity and chronic immune activation in HCV/HIV-1 co-infection.
    Gonzalez VD; Landay AL; Sandberg JK
    Clin Immunol; 2010 Apr; 135(1):12-25. PubMed ID: 20100670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction between the hepatitis C virus and the immune system.
    Rehermann B
    Semin Liver Dis; 2000; 20(2):127-41. PubMed ID: 10946419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease-specific mechanisms of fibrosis: hepatitis C virus and nonalcoholic steatohepatitis.
    van der Poorten D; George J
    Clin Liver Dis; 2008 Nov; 12(4):805-24, ix. PubMed ID: 18984468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetics of intrahepatic hepatitis C virus (HCV)-specific CD4+ T cell responses in HCV and Schistosoma mansoni coinfection: relation to progression of liver fibrosis.
    Kamal SM; Graham CS; He Q; Bianchi L; Tawil AA; Rasenack JW; Khalifa KA; Massoud MM; Koziel MJ
    J Infect Dis; 2004 Apr; 189(7):1140-50. PubMed ID: 15031780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomedicines to reduce inflammation but not viral load in chronic HCV--what's the sense?
    Chuang E; Del Vecchio A; Smolinski S; Song XY; Sarisky RT
    Trends Biotechnol; 2004 Oct; 22(10):517-23. PubMed ID: 15450745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential expression of the CXCR3 ligands in chronic hepatitis C virus (HCV) infection and their modulation by HCV in vitro.
    Helbig KJ; Ruszkiewicz A; Lanford RE; Berzsenyi MD; Harley HA; McColl SR; Beard MR
    J Virol; 2009 Jan; 83(2):836-46. PubMed ID: 18987152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inverse association between hepatic stellate cell apoptosis and fibrosis in chronic hepatitis C virus infection.
    Gonzalez SA; Fiel MI; Sauk J; Canchis PW; Liu RC; Chiriboga L; Yee HT; Jacobson IM; Talal AH
    J Viral Hepat; 2009 Feb; 16(2):141-8. PubMed ID: 19175868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.